BioSpace News Archive

MyMD Pharmaceuticals, Inc. is pleased to announce that its common shares will begin trading , April 19th, on the NASDAQ Stock Market under the ticker symbol “MYMD.”.

Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company’s 2021 first quarter earnings investor webcast on Thursday,

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio’s lead drug candidate, Ampion

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close.

Advanced Human Imaging Limited (ASX: AHI) (“AHI” or the “Company”) is pleased to announce that it has signed a Letter of Intent (LOI) for the proposed acquisition of Israeli-based musculoskeletal assessment company Physimax Technologies Limited (Physimax).

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2021 financial results. ViewRay will hold a conference call to discuss results on Thursday, May 6, 2021 at 4:30 p.m. ET / 1:30 p.m. PT .

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2021 earnings results on Wednesday, May 5, 2021, after the close of the market.

- Company highlights dedication to patients, employees, the community, the environment, and shareholders through initiatives focused on responsibility and sustainability, diversity and inclusion, and patient commitment

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Protara Therapeutics, Inc., a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 120,000 shares of common stock to Martín Sebastian Olivo, M.D., Protara’s newly appointed Chief Medical Officer.